Literature DB >> 10328238

Role of NK and T cells in IL-12-induced anti-tumor response against hepatic colon carcinoma.

K B Pham-Nguyen1, W Yang, R Saxena, S N Thung, S L Woo, S H Chen.   

Abstract

IL-12 is an immuno-regulatory cytokine that has been shown to generate a potent NK and Th1 response in a variety of laboratory models. However, the detailed immune development in the hepatic tumor model by IL-12-mediated gene therapy has not been clarified. In our previous study, intra-tumoral transfer of Adv.mIL-12 (5 x 10(8) pfu) to the MCA26 colon carcinoma liver tumor induced an effective anti-tumor response, extending the median survival time from 29 to over 54 days, while 25% of the animals became tumor-free after a single treatment. In this work, we show that NK cells are responsible for the early, and both NK and T cells for the long-term, Adv.mIL-12-induced immune response. Immunohistopathological analysis of the tumor and in vitro cytotoxicity study of the mononuclear cells of the liver show that NK cells are the first to infiltrate and mediate tumor cell killing, as early as 48 hr after Adv.mIL-12 treatment. In vivo and in vitro depletion of these cells completely abolishes this early anti-tumor response. This activity can be observed in both populations of conventional NK and NKT cells in vitro and in athymic nude mice in vivo. However, the early NK response alone is not sufficient. In vivo T-cell depletion in both the primary tumor treatment and the long-term survival rechallenge study reveals that T cells in addition to NK cells are required in the development of the long-term survival and immunity attributed to Adv.mIL-12 gene therapy in this orthotopic tumor model of colon carcinoma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10328238     DOI: 10.1002/(sici)1097-0215(19990531)81:5<813::aid-ijc24>3.0.co;2-i

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

1.  Interleukin 12 secretion enhances antitumor efficacy of oncolytic herpes simplex viral therapy for colorectal cancer.

Authors:  J J Bennett; S Malhotra; R J Wong; K Delman; J Zager; M St-Louis; P Johnson; Y Fong
Journal:  Ann Surg       Date:  2001-06       Impact factor: 12.969

2.  An orthotopic colon cancer model for studying the B7-H3 antitumor effect in vivo.

Authors:  Catalin M Lupu; Christoph Eisenbach; Michael A Kuefner; Jan Schmidt; Alaviana D Lupu; Wolfgang Stremmel; Jens Encke
Journal:  J Gastrointest Surg       Date:  2006-05       Impact factor: 3.452

3.  Combined gene therapy of endostatin and interleukin 12 with polyvinylpyrrolidone induces a potent antitumor effect on hepatoma.

Authors:  Pei-Yuan Li; Ju-Sheng Lin; Zuo-Hua Feng; Yu-Fei He; He-Jun Zhou; Xin Ma; Xiao-Kun Cai; De-An Tian
Journal:  World J Gastroenterol       Date:  2004-08-01       Impact factor: 5.742

Review 4.  Localized Interleukin-12 for Cancer Immunotherapy.

Authors:  Khue G Nguyen; Maura R Vrabel; Siena M Mantooth; Jared J Hopkins; Ethan S Wagner; Taylor A Gabaldon; David A Zaharoff
Journal:  Front Immunol       Date:  2020-10-15       Impact factor: 7.561

5.  Anti-G-CSF treatment induces protective tumor immunity in mouse colon cancer by promoting protective NK cell, macrophage and T cell responses.

Authors:  Katherine T Morris; Eliseo F Castillo; Anita L Ray; Lea L Weston; Robert A Nofchissey; Joshua A Hanson; Von G Samedi; Irina V Pinchuk; Laurie G Hudson; Ellen J Beswick
Journal:  Oncotarget       Date:  2015-09-08

Review 6.  Non-canonical PD-1 signaling in cancer and its potential implications in clinic.

Authors:  Haoran Zha; Ying Jiang; Xi Wang; Jin Shang; Ning Wang; Lei Yu; Wei Zhao; Zhihua Li; Juan An; Xiaochun Zhang; Huoming Chen; Bo Zhu; Zhaoxia Li
Journal:  J Immunother Cancer       Date:  2021-02       Impact factor: 13.751

7.  The tumor microenvironment: a pitch for multiple players.

Authors:  Giovanna Schiavoni; Lucia Gabriele; Fabrizio Mattei
Journal:  Front Oncol       Date:  2013-04-17       Impact factor: 6.244

Review 8.  Targeted Cellular Micropharmacies: Cells Engineered for Localized Drug Delivery.

Authors:  Thomas J Gardner; Christopher M Bourne; Megan M Dacek; Keifer Kurtz; Manish Malviya; Leila Peraro; Pedro C Silberman; Kristen C Vogt; Mildred J Unti; Renier Brentjens; David Scheinberg
Journal:  Cancers (Basel)       Date:  2020-08-05       Impact factor: 6.639

9.  The Role of Tumor-Infiltrating B Cells in Tumor Immunity.

Authors:  Fei Fei Guo; Jiu Wei Cui
Journal:  J Oncol       Date:  2019-09-24       Impact factor: 4.375

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.